Metraipolis › archive › dc_2a732900904e

5-APDI — Wikipedia (en)

Source
Wikipedia (en)
Original
https://en.wikipedia.org/wiki/5-APDI
License (as archived)
CC-BY-SA-4.0
Archived
2026-11-06T17:26:36.263Z
SHA-256 of the archived text
3f5bf832dd735a0510bcb9bcd8780658614af74b1a59245d9a066d26406b0cdd
Stable URL of this page
https://metraipolis.com/documento/dc_2a732900904e

How to cite

5-APDI — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/5-APDI (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_2a732900904e (Metraipolis archive dc_2a732900904e, sha256 3f5bf832dd735a0510bcb9bcd8780658614af74b1a59245d9a066d26406b0cdd)
BibTeX
@misc{dc2a732900904e,
  title = {5-APDI — Wikipedia (en)},
  howpublished = {Wikipedia (en)},
  url = {https://en.wikipedia.org/wiki/5-APDI},
  note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_2a732900904e; sha256 3f5bf832dd735a0510bcb9bcd8780658614af74b1a59245d9a066d26406b0cdd},
  year = {2026}
}

Archived text

Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/5-APDI. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

5-(2-Aminopropyl)-2,3-dihydro-1H-indene (5-APDI), also known as indanylaminopropane (IAP), 2-aminopropylindane (2-API), indanametamine, and, incorrectly, as indanylamphetamine, is an entactogen and psychedelic drug of the amphetamine family. It has been sold by online vendors through the Internet and has been encountered as a designer drug since 2003, but its popularity and availability has diminished in recent years. 5-APDI appears to act as a potent and weakly selective serotonin releasing agent (SSRA) with IC50 values of 82 nM, 1,848 nM, and 849 nM for inhibiting the reuptake of serotonin, dopamine, and norepinephrine, respectively. It fully substitutes for MBDB but not amphetamine in trained animals, though it does produce disruption for the latter at high doses. 5-APDI has been classified as a class B drug under the Misuse of Drugs Act 1971 since 10 June 2014. The fusion of 5-APDI with 3,3-diphenylpropylamine was reported in a 1968 patent. The dose (of the HCl salt) was judged to be 55mg per tablet (corr. to 50mg of the Fb). The compound had valuable pharmacodynamic properties whilst its toxicity was low. It produces a vasodilatation and thus improves peripheral blood circulation and a pronounced coronary dilatation. The compound further exhibits a blood pressure lowering effect and is therefore indicated for use in the treatment of hypertonia and circulatory illnesses, especially Angina pectoris and other stenocardiac disorders and in the treatment of organic or functional coronary insufficiencies and peripheral blood circulation disorders.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico).
Fonte: Wikipedia in inglese, voce «5-APDI» — https://en.wikipedia.org/wiki/5-APDI
Wikidata Q4639572: «composto chimico» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q4639572
Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/5-APDI?action=history).
Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza.
Estratto dell'introduzione non modificato nel contenuto; revisione 1374402949, consultata il 2026-11-06T17:22:38.074Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: b9cfd63eaeca85498506c64499a85c3bcec894032ec1a5645060ffccb30e7008